Prognostic Importance of Subclassifying Diffuse Large B-Cell Lymphomas
Author Information
Author(s): Baars J W, Jong D de, Willemse E M, Gras L, Dalesio O, Heerde P v, Huygens P C, Lelie H v d, Borne A E G Kr v.d.
Primary Institution: Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
Hypothesis
Does histological subclassification of diffuse large B-cell non-Hodgkin lymphomas have clinical significance?
Conclusion
Patients with immunoblastic or centroblastic polymorphic non-Hodgkin lymphomas have a worse prognosis compared to those with centroblastic non-Hodgkin lymphoma.
Supporting Evidence
- The study included 177 patients with different subtypes of diffuse large B-cell non-Hodgkin lymphoma.
- Patients with immunoblastic lymphoma had a 5-year overall survival of 39.1%.
- Centroblastic lymphoma patients had a 5-year overall survival of 56.3%.
Takeaway
This study found that some types of lymphoma are more serious than others, which can help doctors decide how to treat patients.
Methodology
Retrospective analysis of patient records and histological slides from a specific treatment center.
Potential Biases
Potential bias in patient selection and classification of lymphoma subtypes.
Limitations
The study is retrospective and may not account for all variables affecting prognosis.
Participant Demographics
Patients diagnosed with various subtypes of diffuse large B-cell non-Hodgkin lymphoma between 1984 and 1994.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website